000285472 001__ 285472
000285472 005__ 20260309094001.0
000285472 0247_ $$2doi$$a10.1002/mds.70103
000285472 0247_ $$2pmid$$apmid:41317029
000285472 0247_ $$2pmc$$apmc:PMC12951271
000285472 0247_ $$2ISSN$$a0885-3185
000285472 0247_ $$2ISSN$$a1531-8257
000285472 037__ $$aDZNE-2026-00249
000285472 041__ $$aEnglish
000285472 082__ $$a610
000285472 1001_ $$aMarinescu, Alina-Măriuca$$b0
000285472 245__ $$aCerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.
000285472 260__ $$aNew York, NY$$bWiley$$c2026
000285472 3367_ $$2DRIVER$$aarticle
000285472 3367_ $$2DataCite$$aOutput Types/Journal article
000285472 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1773045513_14562
000285472 3367_ $$2BibTeX$$aARTICLE
000285472 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285472 3367_ $$00$$2EndNote$$aJournal Article
000285472 520__ $$aThe activation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome and associated immune dysregulation is one of the key pathological processes preceding and accompanying α-synuclein pathology, neuronal damage, and cell death in Parkinson's disease (PD). Biomarkers indicative of ongoing immune dysregulation could potentially serve as early indicators of disease activity and may support the development of novel immunomodulatory therapies.We performed a meta-analysis on 17 biomarkers related to specific components of the neuroinflammatory response in the cerebrospinal fluid of people with PD (PwP) and controls. We included studies that measured biomarkers related to NLRP3 inflammasome priming and activation (interleukin [IL]-1β, IL-18, IL-6, C-reactive protein, tumor necrosis factor [TNF]-α); reactive glial cells (soluble triggering receptor expressed on myeloid cells 2, chitinase 3-like-protein 1, glial fibrillary acidic protein, and s100); neurodegeneration (neurofilament light chain [NfL]); and other inflammatory mediators (interferon-ɣ, IL-2, IL-4, IL-8, IL-10, monocyte chemoattractant protein-1, chemokine C-X3-C motif chemokine ligand 1).Random-effects meta-analyses show markers downstream of the NLRP3 inflammasome priming and activation (IL-1β, IL-6, TNF-α), the astrocytic marker s100 calcium-binding protein B and neuroaxonal damage marker NfL are significantly increased in the cerebrospinal fluid (CSF) of PwP.The elevation in key downstream and general inflammatory mediators results is consistent with the hypothesized involvement of the NLRP3 inflammasome pathway and neurodegeneration in PD pathogenesis. These results highlight the potential use of CSF inflammatory markers and support further investigation into immunomodulatory strategies for PD. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000285472 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285472 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285472 650_7 $$2Other$$aBiomarker
000285472 650_7 $$2Other$$aCSF
000285472 650_7 $$2Other$$aInflammation
000285472 650_7 $$2Other$$aNLRP3
000285472 650_7 $$2Other$$aParkinson's disease
000285472 650_7 $$2NLM Chemicals$$aNLR Family, Pyrin Domain-Containing 3 Protein
000285472 650_7 $$2NLM Chemicals$$aBiomarkers
000285472 650_7 $$2NLM Chemicals$$aNLRP3 protein, human
000285472 650_7 $$2NLM Chemicals$$aInflammasomes
000285472 650_2 $$2MeSH$$aHumans
000285472 650_2 $$2MeSH$$aParkinson Disease: cerebrospinal fluid
000285472 650_2 $$2MeSH$$aParkinson Disease: immunology
000285472 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: cerebrospinal fluid
000285472 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: metabolism
000285472 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: immunology
000285472 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000285472 650_2 $$2MeSH$$aInflammasomes
000285472 7001_ $$aMachado, Venissa$$b1
000285472 7001_ $$aPagano, Gennaro$$b2
000285472 7001_ $$aMuelhardt, Nicoletta Milani$$b3
000285472 7001_ $$aKustermann, Thomas$$b4
000285472 7001_ $$aMracsko, Eva Zsuzsanna$$b5
000285472 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b6
000285472 7001_ $$aShariati, Nima$$b7
000285472 7001_ $$aAnzures-Cabrera, Judith$$b8
000285472 7001_ $$00009-0008-7350-5700$$aZinnhardt, Bastian$$b9
000285472 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.70103$$gVol. 41, no. 2, p. 466 - 477$$n2$$p466 - 477$$tMovement disorders$$v41$$x0885-3185$$y2026
000285472 8564_ $$uhttps://pub.dzne.de/record/285472/files/DZNE-2026-00249.pdf$$yRestricted
000285472 8564_ $$uhttps://pub.dzne.de/record/285472/files/DZNE-2026-00249.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285472 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285472 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285472 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-10$$wger
000285472 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-10$$wger
000285472 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-10
000285472 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2025-11-10
000285472 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000285472 980__ $$ajournal
000285472 980__ $$aEDITORS
000285472 980__ $$aVDBINPRINT
000285472 980__ $$aI:(DE-2719)1210000
000285472 980__ $$aUNRESTRICTED